State Street’s Eterna Therapeutics ERNA Stock Holding History

State Street’s Portfolio ERNA Stock Details ERNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-12	Closed	-$23K	–	4875
2022 Q3	$23K	Hold	12	–	–	﹤0.01%	4806
2022 Q2	$48K	Sell	12 -59	-83%	-$423K	﹤0.01%	4730
2022 Q1	$1.09M	Buy	71 +3	+4%	+$56.9K	﹤0.01%	3779
2021 Q4	$2.12M	Buy	68 +1	+1%	+$54.4K	﹤0.01%	3615
2021 Q3	$4.65M	Buy	67 +8	+14%	+$691K	﹤0.01%	3275
2021 Q2	$7.91M	Buy	+59	New	+$8.5M	﹤0.01%	3031

Other funds holding ERNA

Naviter Wealth Little Rock, Arkansas $801M AUM 22.2% 1-Year Est. Return

CPWM

Cypress Point Wealth Management Dallas, Texas $492M AUM 22.57% 1-Year Est. Return

Corient Private Wealth Miami, Florida $69.9B AUM 22.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

State Street's ERNA Position: Q4 2022 in Review

State Street sold out of Eterna Therapeutics (ERNA) in Q4 2022, closing a stake of 12 shares — an estimated $23K sold.

State Street first reported a position in ERNA in Q2 2021 and held it in 6 quarters. The position peaked at $7.91M in Q2 2021. 11 funds tracked by Wall St. Rank hold ERNA as of Q4 2022.

State Street reported no remaining Eterna Therapeutics position as of Q4 2022 after selling out during the quarter.
State Street sold 12 Eterna Therapeutics shares in Q4 2022, an estimated $23K.
State Street first reported a position in Eterna Therapeutics in Q2 2021 and held it in 6 quarters.
State Street's Eterna Therapeutics position peaked at $7.91M in Q2 2021.
11 funds tracked by Wall St. Rank held Eterna Therapeutics as of Q4 2022.

Based on State Street's 13F filing for Q4 2022, filed 14 Feb 2023.